Press release
Lupus Nephritis Market Anticipated to Expand Rapidly During 2024-2034, Analyzes DelveInsight | Roche, Genentech, Astrazeneca, Equillium, Novartis, BeiGene, Boehringer Ingelheim
The Lupus Nephritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lupus Nephritis pipeline products will significantly revolutionize the Lupus Nephritis market dynamics.
DelveInsight's "Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Lupus Nephritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lupus Nephritis Market Forecast [https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Lupus Nephritis Market Report:
*
The Lupus Nephritis market size was valued at USD 1,120 Million in the year 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In November 2024, Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, announced that the first lupus nephritis (LN) patient has been treated in the Phase 1 trial of ADI-001 for autoimmune conditions.
*
In November 2024, Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company specializing in cell therapies for autoimmune diseases, announced plans to present updated clinical data from lupus nephritis (LN) patients treated with KYV-101. These results stem from the ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase 1/2 studies and named patient treatments. In collaboration with leading academic partners, Kyverna will showcase data from six patients treated with the target dose of 1 times 10 CD19 CAR T cells, including four with at least six months of follow-up. All patients with six-month follow-ups have demonstrated sustained efficacy and durability across various key clinical metrics.
*
In October 2024, Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotech company focused on developing novel small molecules for immune-mediated diseases, announced that the U.S. Food and Drug Administration (FDA) has placed the zetomipzomib Investigational New Drug (IND) application for lupus nephritis (LN) on clinical hold. This decision came after Kezar voluntarily paused enrollment and dosing in its Phase 2b PALIZADE clinical trial for active LN, following a recommendation from the Independent Data Monitoring Committee (IDMC). The IDMC's recommendation was based on emerging safety data, including the occurrence of four Grade 5 (fatal) serious adverse events (SAEs) in trial participants from the Philippines and Argentina.
*
In 2023, the United States held the largest portion of the market among the 7 Major Markets (7MM), amounting to 60%, with the UK following closely behind.
*
In November 2023, Roivant and Priovant released findings from their Phase II trial assessing oral brepocitinib in adults with moderate to severe active lupus. The study revealed that brepocitinib did not achieve its primary goal of demonstrating a Systemic Lupus Erythematosus Responder Index change of 4 (SRI-4) at Week 52.
*
In November 2023, Otsuka Pharmaceutical has filed a New Drug Application (NDA) with the Japanese Ministry of Health seeking approval for voclosporin to be used in the treatment of lupus nephritis in Japan.
*
In September 2023, Kyowa Kirin has announced the approval of a biosimilar of rituximab to treat patients with lupus nephritis who have not responded adequately to standard therapies.
*
In 2023, the market size for lupus nephritis in the EU4 countries and the UK was about USD 300 million.
*
Pennesi and Benvenuto (2023) observed that lupus nephritis is more prevalent among children, occurring in 32-55% of cases, and tends to be more severe in this age group.
*
According to DelveInsight, the total number of existing cases of systemic lupus erythematosus in the 7 Major Markets (7MM) was approximately 660,000 in 2023.
*
Key Lupus Nephritis Companies: Hoffmann-La Roche, Genentech, Inc., Astrazeneca, Equillium, Novartis Pharmaceuticals, BeiGene, Boehringer Ingelheim, and others
*
Key Lupus Nephritis Therapies: Obinutuzumab, Mycophenolate Mofetil, Anifrolumab, Itolizumab, Myfortic, Zanubrutinib, and others
Lupus Nephritis Overview
Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease. It specifically refers to inflammation of the kidneys caused by the immune system mistakenly attacking the kidney tissues.
Get a Free sample for the Lupus Nephritis Market Report:
https://www.delveinsight.com/report-store/lupus-nephritis-market [https://www.delveinsight.com/report-store/lupus-nephritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Lupus Nephritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Lupus Nephritis Epidemiology Segmentation:
The Lupus Nephritis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Lupus Nephritis
*
Prevalent Cases of Lupus Nephritis by severity
*
Gender-specific Prevalence of Lupus Nephritis
*
Diagnosed Cases of Episodic and Chronic Lupus Nephritis
Download the report to understand which factors are driving Lupus Nephritis epidemiology trends @ Lupus Nephritis Epidemiological Insights [https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Lupus Nephritis Market
The dynamics of the Lupus Nephritis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Obinutuzumab, Myfortic, and others during the forecasted period 2020-2034.
Lupus Nephritis Therapies and Key Companies
*
Obinutuzumab: Hoffmann-La Roche
*
Mycophenolate Mofetil: Genentech, Inc.
*
Anifrolumab: Astrazeneca
*
Itolizumab: Equillium
*
Myfortic: Novartis Pharmaceuticals
*
Zanubrutinib: BeiGene
To know more about Lupus Nephritis treatment, visit @ Lupus Nephritis Medications [https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Lupus Nephritis Market Drivers
*
Increase in research activities
*
Increasing disease prevalence
*
Surge in a number of clinical studies
Lupus Nephritis Market Barriers
*
High Lupus Nephritis Treatment costs
*
Need for novel Lupus Nephritis therapeutics
*
Surge in a number of clinical studies
*
Need for targeted treatment regimen
Scope of the Lupus Nephritis Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Lupus Nephritis Companies: Hoffmann-La Roche, Genentech, Inc., Astrazeneca, Equillium, Novartis Pharmaceuticals, BeiGene, Boehringer Ingelheim, and others
*
Key Lupus Nephritis Therapies: Obinutuzumab, Mycophenolate Mofetil, Anifrolumab, Itolizumab, Myfortic, Zanubrutinib, and others
*
Lupus Nephritis Therapeutic Assessment: Lupus Nephritis current marketed and Lupus Nephritis emerging therapies
*
Lupus Nephritis Market Dynamics: Lupus Nephritis market drivers and Lupus Nephritis market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Lupus Nephritis Unmet Needs, KOL's views, Analyst's views, Lupus Nephritis Market Access and Reimbursement
Discover more about therapies set to grab major Lupus Nephritis market share @ Lupus Nephritis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Lupus Nephritis Market Report Introduction
2. Executive Summary for Lupus Nephritis
3. SWOT analysis of Lupus Nephritis
4. Lupus Nephritis Patient Share (%) Overview at a Glance
5. Lupus Nephritis Market Overview at a Glance
6. Lupus Nephritis Disease Background and Overview
7. Lupus Nephritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Lupus Nephritis
9. Lupus Nephritis Current Treatment and Medical Practices
10. Lupus Nephritis Unmet Needs
11. Lupus Nephritis Emerging Therapies
12. Lupus Nephritis Market Outlook
13. Country-Wise Lupus Nephritis Market Analysis (2020-2034)
14. Lupus Nephritis Market Access and Reimbursement of Therapies
15. Lupus Nephritis Market Drivers
16. Lupus Nephritis Market Barriers
17. Lupus Nephritis Appendix
18. Lupus Nephritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lupus-nephritis-market-anticipated-to-expand-rapidly-during-20242034-analyzes-delveinsight-roche-genentech-astrazeneca-equillium-novartis-beigene-boehringer-ingelheim]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lupus Nephritis Market Anticipated to Expand Rapidly During 2024-2034, Analyzes DelveInsight | Roche, Genentech, Astrazeneca, Equillium, Novartis, BeiGene, Boehringer Ingelheim here
News-ID: 3807971 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Lupus
Cutaneous Lupus Erythematosus (CLE) Market
Introduction
Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disorder, often associated with systemic lupus erythematosus (SLE), that presents as inflammation, rashes, and photosensitivity. While CLE is rarely fatal, it significantly affects patients' physical and emotional well-being, often leading to scarring, disfigurement, and social stigma.
Over the past decade, the market for CLE therapies has gained global importance as research into autoimmunity has accelerated and biologic therapies have transformed dermatology. Rising…
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Cutaneous Lupus Erythematosus (CLE) Market
Market Overview:
The Global Cutaneous Lupus Erythematosus (CLE) Market is forecasted to achieve a High CAGR during the period 2023-2030. CLE encompasses a spectrum of dermatological symptoms that may precede or accompany systemic lupus erythematosus (SLE), an autoimmune condition impacting multiple organs. Timely diagnosis and treatment of CLE can prevent the onset of severe systemic symptoms.
Market Dynamics:
Drivers:
Rise in Clinical Studies: Technological advancements leading to faster and accurate diagnosis have spurred additional…
Lupus Nephritis Treatment Market 2030
Global Lupus Nephritis Treatment market is expected to be worth roughly USD 8,048 million by 2030, growing at a CAGR of 7.3% during the forthcoming period of 2022-2030, according to Ameco Research
Lupus nephritis is one of the most rapidly spreading diseases over the globe. The increasing frequency of lupus nephritis and consumer awareness has fuelled the worldwide lupus nephritis treatment market. Another crucial factor driving the pace of growth of…
Lupus Erythematosus Market -API Insights, 2017
Summary
Orbis Research Present “Lupus Erythematosus-API Insights, 2017”
Description
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage…
Global Systemic Lupus Erythematosus and Lupus Nephritis Market to Display 10.6% …
"The Report PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz has announced the addition of a new report, titled “PharmaPoint: Systemic Lupus Erythematosus And Lupus Nephritis - Global Drug Forecast And Market Analysis To 2025,” to its expanding repository of research reports. The market…
